Vioxx Sparks Malpractice Debat Following the recent removal of the drug Vioxx from the market, lawmakers are reconsidering a portion of medical malpractice reform. Caps in the malpractice bill would affect pharmaceutical and medical product manufacturers. Democrats oppose the caps, but Sen. Orrin Hatch (R-UT) calls the situation a "feeding frenzy" for trial lawyers. NPR's Julie Rovner reports.
NPR logo

Vioxx Sparks Debate over Malpractice Reform

  • Download
  • <iframe src="https://www.npr.org/player/embed/4181355/4181356" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
Vioxx Sparks Debate over Malpractice Reform

Vioxx Sparks Debate over Malpractice Reform

Vioxx Sparks Debate over Malpractice Reform

  • Download
  • <iframe src="https://www.npr.org/player/embed/4181355/4181356" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">

Following the recent removal of the drug Vioxx from the market, lawmakers are reconsidering a portion of medical malpractice reform. Caps in the malpractice bill would affect pharmaceutical and medical product manufacturers. Democrats oppose the caps, but Sen. Orrin Hatch (R-UT) calls the situation a "feeding frenzy" for trial lawyers. NPR's Julie Rovner reports.